Lymphoma

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

The FDA granted regenerative medicine advanced therapy designation to FT516, a natural killer cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Second-line tisagenlecleucel conferred identical EFS as standard treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, according to randomized phase 3 results presented at ASH Annual Meeting and Exposition.

The addition of polatuzumab vedotin to chemotherapy significantly extended PFS compared with standard first-line treatment for patients with diffuse large B-cell lymphoma, according to results presented at ASH Annual Meeting and Exposition.

The combination of pembrolizumab and vorinostat demonstrated efficacy among patients with relapsed or refractory Hodgkin lymphoma, according to phase 2 study results presented at ASH Annual Meeting and Exposition.

Sixty percent of hematologist-oncologists believe chimeric antigen receptor T-cell therapies provide clinical value at their current price, according to survey results presented at ASH Annual Meeting and Exposition.

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free lymphoma classification, results showed.

Older age, male sex, pre-COVID-19 prognosis of less than 6 months and deferral of ICU care appeared associated with greater risk for mortality among patients with blood cancer and COVID-19, study results showed.

Mosunetuzumab more than quadrupled the complete response rate among patients with relapsed or refractory follicular lymphoma, according to results of a pivotal phase 2 study.

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.